Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
The efficient total synthesis of the recently described natural substance largazole (1) and its active metabolite largazole thiol (2) is described. The synthesis required eight linear steps and proceeded in 37% overall yield. It is demonstrated that largazole is a pro-drug that is activated by removal of the octanoyl residue from the 3-hydroxy-7-mercaptohept-4-enoic acid moiety to generate the active metabolite 2, which is an extraordinarily potent Class I histone deacetylase inhibitor. Synthetic largazole and 2 have been evaluated side-by-side with FK228 and SAHA for inhibition of HDACs 1, 2, 3, and 6. Largazole and largazole thiol were further assayed for cytotoxic activity against a panel of chemoresistant melanoma cell lines, and it was found that largazole is substantially more cytotoxic than largazole thiol; this difference is attributed to differences in the cell permeability of the two substances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, romidepsin and psammaplin A (Figure 15A) contain disulfide bridges that are reduced in the intracellular environment to generate free thiols that are capable of Zn2+-chelation (Figure 15B) [84, 85].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, in cellular contexts, the IC50 values of thiol HDACi decrease significantly, due to reduction/hydrolysis of prodrugs. Whereas in vitro experiments that lack reductants or hydrolases show increased IC50 values of such inhibitors [85, 86].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Yoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Self-citationHistone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Three proteins define a class of human histone deacetylases related to yeast Hda1p
Grozinger, C. M., Hassig, C. A., & Schreiber, S. L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4868 · Cited by 770
Self-citation(2002) · PubMed · Cited by 732
Histone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Kijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Research works printed but not linked: 3
- Townsend P. A., 2007, Chemical Biology, 69, 3
- Yurek-George A., 2004, J. Am. Chem. Soc., 126, 1030, 10.1021/ja039258q · DOI
- Furumai R., 2002, Cancer Res., 62, 4916
Cited by
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
“Results Comparative study of HDAC inhibitors Recently, we reported the optimization of a miniaturized kinetic assay for the biochemical profiling of HDAC1, HDAC2, HDAC3, HDAC6 and HDAC8 (ref”
MethodSelf-citationOrally Absorbed Cyclic Peptides
Nielsen, D. S., Shepherd, N. E., Xu, W., Lucke, A. J., Stoermer, M. J., & Fairlie, D. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00838 · Cited by 445
Bio-mining the microbial treasures of the ocean: New natural products
Imhoff, J. F., Labes, A., & Wiese, J. (2011) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.03.001 · Cited by 346
“Largazole belongs to the histone deacetylase inhibitors (Taori et al., 2008; Bowers et al., 2008).”
BackgroundMuscarine, imidazole, oxazole, and thiazole alkaloids
Jin, Z. (2011) · Natural Product Reports · doi:10.1039/c0np00074d · Cited by 311
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes
Lombardi, P. M., Cole, K. E., Dowling, D. P., & Christianson, D. W. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.004 · Cited by 277
“The resulting largazole thiol is a potent inhibitor of several HDAC isozymes [48, 49], and modification of the depsipeptide skeleton yields analogues that are even more potent inhibitors than largazole itself [50•].”
BackgroundProbing the Biology of Natural Products: Molecular Editing by Diverted Total Synthesis
Szpilman, A. M., & Carreira, E. M. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904761 · Cited by 221
Panning for chemical gold: marine bacteria as a source of new therapeutics
Williams, P. G. (2009) · Trends in Biotechnology · doi:10.1016/j.tibtech.2008.10.005 · Cited by 212
Thiazole and Oxazole Alkaloids: Isolation and Synthesis
Davyt, D., & Serra, G. (2010) · Marine Drugs · doi:10.3390/md8112755 · Cited by 184
“During 2008 seven more syntheses of largazole were reported [22–28].”
BackgroundLargazole: From discovery to broad-spectrum therapy
Hong, J., & Luesch, H. (2012) · Natural Product Reports · doi:10.1039/c2np00066k · Cited by 174
Mazard, S., Penesyan, A., Ostrowski, M. D., Paulsen, I. T., & Egan, S. (2016) · Marine Drugs · doi:10.3390/md14050097 · Cited by 190
“were shown to have high activity towards HDAC: the potent and selective anti-proliferative santacruzamate A (Figure 2) [92] and the cyclic dipepsipeptide largazole specific to class I HDAC (Figure 2) [93–96].”
BackgroundBiological targets and mechanisms of action of natural products from marine cyanobacteria
Salvador-Reyes, L. A., & Luesch, H. (2015) · Natural Product Reports · doi:10.1039/c4np00104d · Cited by 162
Chasing the treasures of the sea — bacterial marine natural products
Gulder, T. A., & Moore, B. S. (2009) · Current Opinion in Microbiology · doi:10.1016/j.mib.2009.05.002 · Cited by 135
Tan, L. T. (2010) · Journal of Applied Phycology · doi:10.1007/s10811-010-9506-x · Cited by 148
“It was demonstrated that the free thiol molecule, 29, showed significant activity against class I HDAC enzymes (HDAC1, HDAC2, and HDAC3) in the picomolar range (Bowers et al. 2008).”
BackgroundInfluentialMarinopyrrole A Target Elucidation by Acyl Dye Transfer
Hughes, C. C., Yang, Y., Liu, W.-T., Dorrestein, P. C., Clair, J. J. L., & Fenical, W. (2009) · Journal of the American Chemical Society · doi:10.1021/ja903149u · Cited by 127
Heteroaryl Rings in Peptide Macrocycles
Smolyar, I. V., Yudin, A. K., & Nenajdenko, V. G. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00789 · Cited by 136
Itoh, H., & Inoue, M. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00063 · Cited by 120
Cyclic Peptides: Promising Scaffolds for Biopharmaceuticals
Gang, D., Kim, D.-W., & Park, H.-S. (2018) · Genes · doi:10.3390/genes9110557 · Cited by 113
“The protecting group is cleaved by enzymes after translocation of largazole into the cytoplasm, and the exposed thiol group combines with a zinc ion cofactor in HDAC to inhibit its activity [14].”
BackgroundSynthesis and Conformation−Activity Relationships of the Peptide Isosteres of FK228 and Largazole
Bowers, A. A., Greshock, T. J., West, N., Estiu, G., Schreiber, S. L., Wiest, O., Williams, R. M., & Bradner, J. E. (2009) · Journal of the American Chemical Society · doi:10.1021/ja807772w · Cited by 104
Self-citationBowers, A. A., West, N., Newkirk, T. L., Troutman-Youngman, A. E., Schreiber, S. L., Wiest, O., Bradner, J. E., & Williams, R. M. (2009) · Organic Letters · doi:10.1021/ol900078k · Cited by 103
Self-citationLiu, Y., Wang, Z., Wang, J., Lam, W., Kwong, S., Li, F., Friedman, S. L., Zhou, S., Ren, Q., Xu, Z., et al. (2012) · Liver International · doi:10.1111/liv.12034 · Cited by 98
“Largazole can be considered as a prodrug and the corresponding largazole thiol is its reactive form that inhibits class I histone deacetylases (HDACs) with high potency against HDAC1, HDAC2 and HDAC3 in the picomolar range (12).”
BackgroundHowell, P., Liu, S., Ren, S., Behlen, C., Fodstad, Ø., & Riker, A. I. (2009) · Cancer Control · doi:10.1177/107327480901600302 · Cited by 100
Sanchez, G. J., Richmond, P. A., Bunker, E. N., Karman, S. S., Azofeifa, J. G., Garnett, A. T., Xu, Q., Wheeler, G. E., Toomey, C. M., Zhang, Q., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1225 · Cited by 94
A review of pharmacological and toxicological potentials of marine cyanobacterial metabolites
Nagarajan, M., Veerabadhran, M., & Sundararaman, M. (2011) · Journal of Applied Toxicology · doi:10.1002/jat.1717 · Cited by 101
Macrocyclic Histone Deacetylase Inhibitors
C. Mwakwari, S., Patil, V., Guerrant, W., & K. Oyelere, A. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610792232079 · Cited by 88
“macrocyclic depsipeptide that exhibits potent biological activity as well as high HDAC1 selectivity [40, 109].”
BackgroundHDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
Karagiannis, D., & Rampias, T. N. (2021) · Cancers · doi:10.3390/cancers13143575 · Cited by 95
“Interestingly, HDAC11 was reported to be a target of romidepsin, largazole [11], and entinostat [16]; however, this should be confirmed by additional studies.”
BackgroundOlsen, C. A., & Ghadiri, M. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900850t · Cited by 91
Zeng, X., Yin, B., Hu, Z., Liao, C., Liu, J., Li, S., Li, Z., Nicklaus, M. C., Zhou, G., & Jiang, S. (2010) · Organic Letters · doi:10.1021/ol100308a · Cited by 85
(+)- and (−)-Mutisianthol: First Total Synthesis, Absolute Configuration, and Antitumor Activity
Bianco, G. G., Ferraz, H. M. C., Costa, A. M., Costa-Lotufo, L. V., Pessoa, C., de Moraes, M. O., Schrems, M. G., Pfaltz, A., & Silva, L. F. (2009) · The Journal of Organic Chemistry · doi:10.1021/jo9000405 · Cited by 84
Synthesis and Activity of Largazole Analogues with Linker and Macrocycle Modification
Ying, Y., Liu, Y., Byeon, S. R., Kim, H., Luesch, H., & Hong, J. (2008) · Organic Letters · doi:10.1021/ol801532s · Cited by 84
Strategies in developing promising histone deacetylase inhibitors
Zhang, L., Fang, H., & Xu, W. (2009) · Medicinal Research Reviews · doi:10.1002/med.20169 · Cited by 87
“Bowers and coworkers demonstrated that largazole is, in fact, a pro-drug, and largazole thiol (32) is its active form.(94) Their finding is supported by HDAC1, 2, 3, and 6 inhibitory activity data (Ki, nM) of 0.”
BackgroundMontero, A., Beierle, J. M., Olsen, C. A., & Ghadiri, M. R. (2009) · Journal of the American Chemical Society · doi:10.1021/ja809508f · Cited by 94
Souto, J. A., Vaz, E., Lepore, I., Pöppler, A., Franci, G., Álvarez, R., Altucci, L., & de Lera, Á. R. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100244y · Cited by 90
Jourden, J. L. M., Daniel, K. B., & Cohen, S. M. (2011) · Chemical Communications · doi:10.1039/c1cc12526e · Cited by 89
Recent advances in marine drug research
Vinothkumar, S., & Parameswaran, P. S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.02.006 · Cited by 79
“Further biological studies using synthetic sample revealed that Largazole (99) is a potent histone deacetylase (HDAC) class I inhibitor (Bowers et al., 2008; Ying et al., 2008).”
BackgroundHerr, D. J., Baarine, M., Aune, S. E., Li, X., Ball, L. E., Lemasters, J. J., Beeson, C., Chou, C. J., & Menick, D. R. (2017) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2017.12.004 · Cited by 79
“HDAC activity was assayed in 5 μg of total rat heart lysate and 5 μg rat heart mitochondrial homogenates using the acetylated lysine aminomethyl-coumarin-Boc substrate, which is a substrate for class I and class IIb HDCACs but not class IIa or class IV HDACs [37,38].”
MethodAdhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Newkirk, T. L., Bowers, A. A., & Williams, R. M. (2009) · Natural Product Reports · doi:10.1039/b817886k · Cited by 81
Self-citationLargazole and Its Derivatives Selectively Inhibit Ubiquitin Activating Enzyme (E1)
Ungermannova, D., Parker, S. J., Nasveschuk, C. G., Wang, W., Quade, B., Zhang, G., Kuchta, R. D., Phillips, A. J., & Liu, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029208 · Cited by 67
“Numerous analogs of Largazole have been generated in efforts to understand the structure-activity relationship, and it has been determined that the thioester moiety is required for HDAC inhibition [21–32].”
BackgroundNon-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity
Auzzas, L., Larsson, A., Matera, R., Baraldi, A., Deschênes-Simard, B., Giannini, G., Cabri, W., Battistuzzi, G., Gallo, G., Ciacci, A., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm101092u · Cited by 63
Yao, Y., Tu, Z., Liao, C., Wang, Z., Li, S., Yao, H., Li, Z., & Jiang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01044 · Cited by 65
Szpilman, A. M., & Carreira, E. M. (2010) · Angewandte Chemie · doi:10.1002/ange.200904761 · Cited by 65
Wang, B., Huang, P.-H., Chen, C., & Forsyth, C. J. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo102478x · Cited by 60
Benelkebir, H., Marie, S., Hayden, A. L., Lyle, J., Loadman, P. M., Crabb, S. J., Packham, G., & Ganesan, A. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.02.024 · Cited by 59
Decroos, C., Clausen, D. J., Haines, B. E., Wiest, O., Williams, R. M., & Christianson, D. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00010 · Cited by 58
Self-citationIndole-Derived Psammaplin A Analogues as Epigenetic Modulators with Multiple Inhibitory Activities
Pereira, R., Benedetti, R., Pérez-Rodríguez, S., Nebbioso, A., García‐Rodríguez, J., Carafa, V., Stuhldreier, M. C., Conte, M., Rodríguez‐Barrios, F., Stunnenberg, H. G., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300618u · Cited by 62
Natural Cyclopeptides as Anticancer Agents in the Last 20 Years
Zhang, J., Xia, Y.-X., & Zhang, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083973 · Cited by 58
“Based on the pharmacological studies carried out by Bowers et al., largazole was considered a potent inhibitor of class I HDACs [281].”
BackgroundInfluentialRobles-Bañuelos, B., Durán-Riveroll, L. M., Rangel‐López, E., Pérez-López, H. I., & González‐Maya, L. (2022) · Molecules · doi:10.3390/molecules27154814 · Cited by 57
In Vitro and In Vivo Osteogenic Activity of Largazole
Lee, S., Kwak, H. B., Pi, S., You, H., Byeon, S. R., Ying, Y., Luesch, H., Hong, J., & Kim, S. H. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1002794 · Cited by 54
Bioactive Secondary Metabolites from Marine Microbes for Drug Discovery
Nikapitiya, C. (2012) · Advances in food and nutrition research · doi:10.1016/b978-0-12-416003-3.00024-x · Cited by 61
“Later on, number of total synthesis has been developed (Bowers et al., 2008; Nasveschuk et al., 2008; Ying et al., 2008) to provide sufficientmaterial to demonstrate the mode of action as a histone deacetylase inhibitor (Bowers et al.”
BackgroundNatural and Synthetic Macrocyclic Inhibitors of the Histone Deacetylase Enzymes
Maolanon, A. R., Kristensen, H. M. E., Leman, L. J., Ghadiri, M. R., & Olsen, C. A. (2016) · ChemBioChem · doi:10.1002/cbic.201600519 · Cited by 51
Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents
Amin, S. A., Adhikari, N., & Jha, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.03.001 · Cited by 53
Natural product mode of action (MOA) studies: a link between natural and synthetic worlds
Clair, J. J. L. (2010) · Natural Product Reports · doi:10.1039/b909989c · Cited by 50
Recent advances in the synthesis and utility of thiazoline and its derivatives
Kumar, S., Arora, A., Sapra, S., Kumar, R., Singh, B. K., & Singh, S. K. (2024) · RSC Advances · doi:10.1039/d3ra06444a · Cited by 51
Halophilic Bacteria: Potentials and Applications in Biotechnology
Mohammadipanah, F., Hamedi, J., & Dehhaghi, M. (2015) · Sustainable development and biodiversity · doi:10.1007/978-3-319-14595-2_11 · Cited by 51
Albert, B. J., Niu, A., Ramani, R., Marshall, G. R., Wender, P. A., Williams, R. M., Ratner, L., Barnes, A. B., & Kyei, G. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07814-4 · Cited by 44
Self-citationBhansali, P. R., Hanigan, C. L., Casero, R. A., & Tillekeratne, L. M. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200432a · Cited by 43
Metal-dependent hormone function: the emerging interdisciplinary field of metalloendocrinology
Stevenson, M. J., Uyeda, K. S., Harder, N. H. O., & Heffern, M. C. (2018) · Metallomics · doi:10.1039/c8mt00221e · Cited by 45
Ahmed, S., Riegsecker, S., Beamer, M. A., Rahman, A., Bellini, J. V., Bhansali, P. R., & Tillekeratne, L. M. V. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.04.014 · Cited by 42
“It has also demonstrated selectivity for class I HDAC enzymes (Bowers et al., 2008; Ying et al., 2008).”
BackgroundProgress in the discovery and development of anticancer agents from marine cyanobacteria
Luesch, H., Ellis, E. K., Chen, Q.-Y., & Ratnayake, R. (2024) · Natural Product Reports · doi:10.1039/d4np00019f · Cited by 43
Li, X., Tu, Z., Li, H., Liu, C., Li, Z., Sun, Q., Yao, Y., Liu, J., & Jiang, S. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300371t · Cited by 43
Total synthesis of antimicrobial and antitumor cyclic depsipeptides
Li, W., Schlecker, A., & Ma, D. (2010) · Chemical Communications · doi:10.1039/c0cc00629g · Cited by 41
Chen, P., Huang, C., Meng, X., & Li, J. (2015) · Biochimie · doi:10.1016/j.biochi.2015.06.016 · Cited by 43
Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors
Chen, F., Chai, H., Su, M., Zhang, Y., Li, J. X., Xie, X., & Nan, F. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400470s · Cited by 42
Epigenetic modulators from “The Big Blue”: A treasure to fight against cancer
Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.005 · Cited by 42
Salvador, L. A., Park, H., Al‐Awadhi, F. H., Liu, Y., Kim, B., Zeller, S. L., Chen, Q.-Y., Hong, J., & Luesch, H. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500170r · Cited by 40
Recent Progress in Histone Deacetylase (HDAC) 1 Inhibitors as Anticancer Agent
Patel, P., Wahan, S. K., Vishakha, S., Kurmi, B. D., Gupta, G. D., Rajak, H., & Asati, V. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220624090542 · Cited by 39
Kitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38
Synthesis and Biological Evaluation of C7‐Demethyl Largazole Analogues
Chen, F., Gao, A., Li, J. X., & Nan, F. (2009) · ChemMedChem · doi:10.1002/cmdc.200900125 · Cited by 39
Chen, Q.-Y., Chaturvedi, P. R., & Luesch, H. (2018) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00352 · Cited by 38
Al‐Awadhi, F. H., Salvador‐Reyes, L. A., Elsadek, L. A., Ratnayake, R., Chen, Q.-Y., & Luesch, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00093 · Cited by 39
Kalin, J. H., Zhang, H., Gaudrel‐Grosay, S., Vistoli, G., & Kozikowski, A. P. (2012) · ChemMedChem · doi:10.1002/cmdc.201100522 · Cited by 35
Total synthesis of spiruchostatin B aided by an automated synthesizer
Fuse, S., Okada, K., Iijima, Y., Munakata, A., Machida, K., Takahashi, T., Takagi, M., Shin‐ya, K., & Doi, T. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob01169j · Cited by 37
Moreno–Yruela, C., Bæk, M., Vrsanova, A.-E., Schulte, C., Maric, H. M., & Olsen, C. A. (2021) · Nature Communications · doi:10.1038/s41467-020-20250-9 · Cited by 36
Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms
Wu, L., Ye, K., Jiang, S., & Zhou, G. (2021) · Marine Drugs · doi:10.3390/md19090488 · Cited by 36
Small-molecule amines: a big role in the regulation of bone homeostasis
Zhang, Q., Yang, J., Hu, N., Liu, J., Yu, H., Pan, H., Chen, D., & Ruan, C. (2023) · Bone Research · doi:10.1038/s41413-023-00262-z · Cited by 35
Total Synthesis of (18S)‐ and (18R)‐Homolargazole by Rhodium‐Catalyzed Hydrocarboxylation
Schotes, C., Ostrovskyi, D., Senger, J., Schmidtkunz, K., Jung, M., & Breit, B. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201303300 · Cited by 35
Inhibition of Zinc-Dependent Histone Deacetylases with a Chemically Triggered Electrophile
Bošković, Ž., Kemp, M. M., Freedy, A. M., Viswanathan, V. S., Pop, M. S., Fuller, J. H., Martínez, N. M., Figueroa-Lazú, S., Hong, J. A., Lewis, T. A., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00012 · Cited by 35
Self-citationRadical‐Mediated Thiol‐Ene Strategy: Photoactivation of Thiol‐Containing Drugs in Cancer Cells
Sun, S., Oliveira, B. L., Jiménez‐Osés, G., & Bernardes, G. J. L. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201811338 · Cited by 35
Evaluation of class I HDAC isoform selectivity of largazole analogues
Kim, B., Park, H., Salvador, L. A., Serrano, P. E., Kwan, J. C., Zeller, S. L., Chen, Q.-Y., Ryu, S., Liu, Y., Byeon, S., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.07.006 · Cited by 35
Calandra, N. A., Cheng, Y. L., Kocak, K. A., & Miller, J. S. (2009) · Organic Letters · doi:10.1021/ol900436f · Cited by 33
Total Synthesis and Stereochemical Assignment of Burkholdac B, a Depsipeptide HDAC Inhibitor
Benelkebir, H., Donlevy, A. M., Packham, G., & Ganesan, A. (2011) · Organic Letters · doi:10.1021/ol202197q · Cited by 33
Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Rangel, M., de Santana, C. J. C., Pinheiro, A., Anjos, L., Barth, T., Júnior, O. R. P., Fontes, W., & Castro, M. S. (2016) · Current Protein and Peptide Science · doi:10.2174/1389203717666160526122130 · Cited by 33
Clausen, D. J., Smith, W. B., Haines, B. E., Wiest, O., Bradner, J. E., & Williams, R. M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.063 · Cited by 32
“Depsipeptide pyridyl “IN” thiol (6)—To a solution of trityl protected thiol 39 (300 mg, 0.”
BackgroundSelf-citationReddy, D. N., Ballante, F., Chuang, T., Pirolli, A., Marrocco, B., & Marshall, G. R. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01632 · Cited by 34
Thioester derivatives of the natural product psammaplin A as potent histone deacetylase inhibitors
Baud, M. G. J., Leiser, T., Petrucci, V., Gunaratnam, M., Neidle, S., Meyer‐Almes, F., & Fuchter, M. J. (2013) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.9.11 · Cited by 34
Peptide Based Macrocycles: Selective Histone Deacetylase Inhibitors with Antiproliferative Activity
Rajak, H., Singh, A. J., Dewangan, P. K., Patel, V. S., Jain, S., Tiwari, S. K., Veerasamy, R., & Sharma, P. C. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320140006 · Cited by 32
“The octanoyl residue in largazole apparently serves a dual role, imparting better cell-permeability and allowing facile presentation of the free thiol within the cell [66].”
BackgroundSynthesis of Thiazolines by Copper Catalyzed Aminobromination of Thiohydroximic Acids
Lemercier, B. C., & Pierce, J. G. (2014) · Organic Letters · doi:10.1021/ol500588v · Cited by 32
Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs
Guerra-Bubb, J. M., Bowers, A. A., Smith, W. B., Paranal, R. M., Estiu, G. L., Wiest, O., Bradner, J. E., & Williams, R. M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.012 · Cited by 31
Self-citationAlmaliti, J., Al-Hamashi, A. A., Negmeldin, A. T., Hanigan, C. L., Perera, L., Pflum, M. K. H., Casero, R. A., & Tillekeratne, L. M. V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01271 · Cited by 30
“3-(Tritylthio)propanal (36)—To a solution of triphenylmethanethiol (1.”
Williams, R. M. (2011) · The Journal of Organic Chemistry · doi:10.1021/jo2003693 · Cited by 30
Self-citationAn Overview of Naturally Occurring Histone Deacetylase Inhibitors
Kim, B., & Hong, J. (2014) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666141208105614 · Cited by 30
“Largazole (113) is a class I-selective HDAC inhibitor (HDAC1 IC50 = 25 nM, HDAC2 IC50 = 21 nM, and HDAC3 IC50 = 48 nM) that only weakly inhibits HDAC6 (IC50 = 5,700 nM) [104, 106].”
Case Studies of the Synthesis of Bioactive Cyclodepsipeptide Natural Products
Stolze, S. C., & Kaiser, M. (2013) · Molecules · doi:10.3390/molecules18021337 · Cited by 29
“Inhibition is thereby achieved by a coordination of their (S)-3-hydroxy-7-mercaptohept-4-enoic acid moiety to the active site Zn2+ residue of HDACs [9,10].”
BackgroundInfluentialSynthesis and biological evaluation of largazole zinc-binding group analogs
Kim, B., Ratnayake, R., Lee, H., Shi, G., Zeller, S. L., Li, C., Luesch, H., & Hong, J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.071 · Cited by 29
Marine Natural Products: New Avenue in Treatment of Osteoporosis
Chaugule, S. R., Indap, M. M., & Chiplunkar, S. V. (2017) · Frontiers in Marine Science · doi:10.3389/fmars.2017.00384 · Cited by 30
“Largazole is a 16 membered macrocycle possessing unusual structural features, includes a substituted 4-methylthiazoline linearly fused to a thiazole and a 3-hydroxy-7-mercaptohept-4-enoic acid unit (Bowers et al., 2008).”
BackgroundDiscovery and Mechanism of Natural Products as Modulators of Histone Acetylation
Salvador, L. A., & Luesch, H. (2012) · Current Drug Targets · doi:10.2174/138945012802008973 · Cited by 32
A solid-phase total synthesis of the cyclic depsipeptide HDAC inhibitor spiruchostatin A
Iijima, Y., Munakata, A., Shin‐ya, K., Ganesan, A., Doi, T., & Takahashi, T. (2009) · Tetrahedron Letters · doi:10.1016/j.tetlet.2009.04.005 · Cited by 27
Li, S., Yao, H., Xu, J., & Jiang, S. (2011) · Molecules · doi:10.3390/molecules16064681 · Cited by 26
“Williams and co-workers [18] synthesized the thiazoline–thiazole subunit 4c by condensation of nitrile 5 and (R)-2-methylcysteine methyl ester hydrochloride under basic conditions (triethylamine in methanol, Scheme 3).”
MethodSulfation Patterns of Saccharides and Heavy Metal Ion Binding
Alshanski, I., Blaszkiewicz, J., Mervinetsky, E., Rademann, J., Yitzchaik, S., & Hurevich, M. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201901538 · Cited by 26
Pilon, J. L., Clausen, D. J., Hansen, R. J., Lunghofer, P. J., Charles, B., Rose, B. J., Thamm, D. H., Gustafson, D. L., Bradner, J. E., & Williams, R. M. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2675-1 · Cited by 26
“The method used for determination of IC50’s to specific HDAC proteins is as reported in [12].”
MethodSelf-citationConcise total synthesis of largazole
Xiao, Q., Wang, L., Jiao, X., Liu, X., Wu, Q., & Xie, P. (2010) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2010.510114 · Cited by 24
Metadata
- Authors
- Bowers, A., West, N., Taunton, J., Schreiber, S. L., Bradner, J. E., & Williams, R. M.
- Affiliations
- Broad Institute (US)
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-07-19
- Volume
- 130
- Issue
- 33
- Pages
- 11219-11222
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- PMC
- PMC3090445
- OpenAlex
- W2082971158
- Cited by
- 165
- References
- 33
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 8 · 2022: 3 · 2021: 10 · 2020: 3 · 2019: 9 · 2018: 6 · 2017: 12 · 2016: 9 · 2015: 12 · 2014: 13 · 2013: 10 · 2012: 10
- FWCI
- 7.82
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Chemical Society (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust
- National Institutes of Health (1p41gm049631-01, n01co12400-79-0-22)
- National Cancer Institute (N01CO12400, N01-CO-012400, K08CA128972, R01CA152314)
- National Institute of General Medical Sciences (GM49631)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Isoquinoline Alkaloid Synthesis
- Keywords
- largazole, total synthesis, prodrugs, class I histone deacetylase inhibitors, romidepsin, vorinostat, HDAC1, HDAC2, HDAC3, HDAC6, cytotoxicity, membrane permeability
- MeSH terms
- Vorinostat, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Enzyme Inhibitors, Humans, Hydroxamic Acids, Molecular Conformation, Stereoisomerism, Structure-Activity Relationship, Sulfhydryl Compounds, Thiazoles, Cell Line, Tumor, Depsipeptides, Cell Proliferation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.